Seth Epstein

  • ASSISTANT PROFESSOR Ophthalmology
Print ProfilePrint Profile

Email

Education

  • B.A., Brandeis University
    Chemistry

  • M.D., Autonomous University of Guadalajara School of Medicine

  • Michigan Cancer Foundation
    Biochemistry & Chemistry

  • New York University Medical Center
    Immuno-Pathology and Immuno-Dermatology

  • Mount Sinai School of Medicine
    Infectious Disease of the Eye

  • Center for Advanced Training in Cell and Molecular Biology
    Cell Culture, Immunocytochemistry and Molecular Biology

Awards

  • -
    Eye Bank Association of America Association for Research in Vision and Ophthalmology, fellowship grant

  • -
    Dermatology Foundation, research grant

  • -
    Outstanding Scientists of the 21st Century

  • -
    Marquis Who's Who in America

  • -
    Marquis Who's Who in Science and Medicine

Research

cornea, Langerhans cells, ocular herpes simplex, laser keratectomy, keratitis, herpetic eye disease

Publications

Epstein S, Jan MS, Skittone LS, Small T, Asbell PA. Evaluation of cytokine-mediated chemotaxis of Ia+ Langerhans cells (LC) into the central cornea of mice: Effect of cyclosporine A (CsA), transforming growth factor (TGF)-b and interferons (IFNs)-a, b and g. Adv Ocular Immunol 1994; 1068: 7-10.

Asbell PA, Epstein S, Wallace JW, Epstein D, Stewart CC, Burger RM. Efficacy of cobalt chelates CTC-23, CTC-67, CTC-82 and CTC-96 for treatment of ocular herpes simplex infection in a rabbit model. Cornea 1997; 17(5): 550-557.

Epstein S, Fisher EM, Sternberg GJ, Franklin W, Gordon R, Ho JJ, Asbell PA. Recurrent Ocular Herpes Simplex Keratitis Following Excimer Laser Photorefractive Keratectomy in Rabbit Model. CLAO J 2001; 27(2): 94-99.

Epstein S, Nurozler M, Smetana CR, Asbell PA. Efficacy of Polyclonal Antibodies for Treatment of Ocular Herpes Simples Infection. Cornea 2001; 20(5): 495-500.

Herpetic Disease Study Group . Predictors of Recurrent Herpes Simplex Virus Keratitis. Cornea 2001; 20(2): 123-128.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Epstein did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

Basic Sciences Building Floor Annenberg 22 Room 18
10 East 101st Street
New York, NY 10029